DNLI - Denali Therapeutics closes down 11% as 2025 operating expenses seen weighing
2025-02-28 16:54:15 ET
More on Denali Therapeutics
- Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
- Denali Therapeutics gets FDA breakthrough therapy designation for its treatment of hunter syndrome
- Denali ALS candidate fails in key study
- Seeking Alpha’s Quant Rating on Denali Therapeutics
- Historical earnings data for Denali Therapeutics